Brazil vs Cote d'Ivoire: The number of people with susceptibility test result for rifampicin
Brazil
50.47
in 2021
Cote d'Ivoire
59.19
in 2021
Brazil rank
114th
Cote d'Ivoire rank
111th
The number of people with susceptibility test result for rifampicin over time
- Brazil
- Cote d'Ivoire
How they compare
Cote d'Ivoire currently reports 59.19 against 50.47 in Brazil, a difference of 8.72.
That makes Cote d'Ivoire's figure about 1.2 times Brazil's.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Brazil ahead.
Brazil ranks 114th and Cote d'Ivoire ranks 111th of 146 countries.
Brazil has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Brazil | Cote d'Ivoire | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 41.74 | 23.43 | 18.31 | Brazil |
| 2020s | 51.96 | 34.58 | 17.38 | Brazil |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Brazil or Cote d'Ivoire?
- Cote d'Ivoire, at 59.19 against 50.47 in Brazil as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Brazil and Cote d'Ivoire?
- 8.72, with Cote d'Ivoire ahead.
- How many years of comparable data are there for Brazil and Cote d'Ivoire?
- 5 years are reported by both, from 2017 to 2021.
- How do Brazil and Cote d'Ivoire rank globally for the number of people with susceptibility test result for rifampicin?
- Brazil ranks 114th and Cote d'Ivoire ranks 111th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.